Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 11/20 | 0.66 |
| ▸ | DRD2 | P14416 | 7/20 | 0.47 |
| ▸ | DRD4 | P21917 | 7/20 | 0.47 |
| ▸ | DRD3 | P35462 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5699930 | 0.87 | CCR5 (0.64) | CCR5DRD2DRD4DRD3KDM4E | |
| SCHEMBL5699985 | 0.85 | CCR5 (0.70) | CCR5DRD2DRD4DRD3KDM4E | |
| SCHEMBL5699886 | 0.83 | CCR5 (0.67) | CCR5DRD2DRD4DRD3KDM4E | |
| SCHEMBL5699954 | 0.83 | CCR5 (0.67) | CCR5DRD2DRD4DRD3KDM4E | |
| SCHEMBL5699730 | 0.82 | CCR5 (0.66) | CCR5DRD2DRD4DRD3KDM4E | |
| SCHEMBL5699791 | 0.82 | CCR5 (0.66) | CCR5DRD2DRD4DRD3KDM4E | |
| SCHEMBL5699938 | 0.82 | CCR5 (0.66) | CCR5DRD2DRD4DRD3KDM4E | |
| SCHEMBL5699672 | 0.82 | CCR5 (0.66) | CCR5DRD2DRD4DRD3KDM4E | |
| SCHEMBL5699870 | 0.82 | CCR5 (0.66) | CCR5DRD2DRD4DRD3KDM4E | |
| SCHEMBL5700182 | 0.82 | CCR5 (0.66) | CCR5DRD2DRD4DRD3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1902171-A | Benzylether amine compounds useful as CCR-5 antagonists | SCHERING AG (DE) | 2007-01-24 | — | — | CN | claimed |
| EP-1687268-A1 | BENZYLETHER AMINE COMPOUNDS USEFUL AS CCR-5 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-08-09 | — | — | EP | claimed |
| WO-2005047249-A1 | BENZYLETHER AMINE COMPOUNDS USEFUL AS CCR-5 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-26 | — | — | WO | claimed |
| US-20050101644-A1 | Benzylether amine compounds useful as CCR-5 antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-12 | — | — | US | claimed |
| CN-1902171-A | Benzylether amine compounds useful as CCR-5 antagonists | SCHERING AG (DE) | 2007-01-24 | — | — | CN | disclosed |
| EP-1687268-A1 | BENZYLETHER AMINE COMPOUNDS USEFUL AS CCR-5 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005047249-A1 | BENZYLETHER AMINE COMPOUNDS USEFUL AS CCR-5 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-26 | — | — | WO | disclosed |
| US-20050101644-A1 | Benzylether amine compounds useful as CCR-5 antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101644-A1 | Benzylether amine compounds useful as CCR-5 antagonists | CCR1, CCR3, CCR4 | CCR5 7/4885DRD2 570/4885DRD4 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.